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Emergence of VanD-type
vancomycin-resistant Enterococcus faecium
in Stockholm, Sweden
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A B S T R A C T
A vancomycin-resistant Enterococcus faecium iso-
late from the urine of a liver transplant patient in
Stockholm was found to contain a vanD gene. The
sequence of the vanD PCR product shared 100%
identity with the vanD5 allele. The isolate was
resistant to a relatively high level of vancomycin
(128 mg ⁄L) and a low level of teicoplanin
(4 mg ⁄L). This is the first VanD-type vancomy-
cin-resistant E. faecium isolate reported in Swe-
den. The emergence of this strain reinforces the
necessity of infection control efforts to interrupt
the spread of these organisms.
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Since the first vancomycin-resistant clinical iso-
lates of Enterococcus spp. were reported in Europe
during 1988 [1,2], vancomycin-resistant entero-
cocci have emerged worldwide and have become
an increasing problem in clinical settings [3,4].
However, the incidence of vancomycin-resistant
enterococci is still low in Sweden (http://
www.strama.se). Resistance to vancomycin re-
sults from the production of low-affinity pepti-
doglycan precursors ending in D-Ala-D-Lac
(VanA, VanB and VanD) or D-Ala-D-Ser (VanC,
VanE and VanG), and from the elimination of
high-affinity precursors [5,6]. Six types of vanco-
mycin resistance have been characterised in en-
terococci, both phenotypically and genotypically.
Five of these types (VanA, B, D, E and G)
correspond to acquired resistance, while VanC is
an intrinsic property of Enterococcus gallinarum
and Enterococcus casseliflavus–Enterococcus flaves-
cens. VanA and VanB are the most common types.
VanE and VanG have been identified in single
strains of Enterococcus faecalis [7,8]. VanD-type
strains are characterised by constitutive resistance
to moderate levels of both vancomycin and
teicoplanin [5,9], and Enterococcus faecium strains
with VanD-type resistance have been reported in
the USA, Canada, Brazil and France [10–15].
The strain (Hyg-39) described in this report was
isolated from the urine of a liver transplant patient
admitted to the intensive care unit of Karolinska
University Hospital Huddinge, Stockholm, Swe-
den during April 2003. The strain was first iden-
tified by standard biochemical tests, and the
identification was then verified by PCR targeting
the ddl (D-Ala:D-Ala ligase) gene of E. faecium.
Antimicrobial susceptibility was determined by
disk-diffusion (Swedish Reference Group for
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Antibiotics; http://www.SRGA.org), Etest (AB
Biodisk, Solna, Sweden) and broth microdilution
(Sensititre dry-form commercial MIC panels;
TREK Diagnostics, East Grinstead, UK). The
strain was resistant to oxacillin, ampicillin, nor-
floxacin, cefadroxil, clindamycin (MIC >16 mg ⁄L)
and vancomycin (MIC 128 mg ⁄L), and was
susceptible to teicoplanin (MIC 4 mg ⁄L), linezo-
lid (MIC 2 mg ⁄L), quinupristin–dalfopristin
(MIC 1 mg ⁄L) and dalbavancin (MIC 1 mg ⁄L).
To investigate the mechanism responsible for
the vancomycin resistance of this strain, a multi-
plex PCR, developed by Depardieu et al. [16], was
used to detect the six types of glycopeptide
resistance characterised in enterococci and to
identify E. faecium and E. faecalis at the species
level. Based on the sequence of the structural gene
for the ligase responsible for resistance (vanA,
vanB, vanC, vanD, vanE or vanG), six resistance
types can be distinguished. E. faecium
CCUG 36804 (vanA), E. faecalis SSI 78 (vanB),
E. gallinarum CCUG 18658 (vanC1), E. casseliflavus
ATCC 25788 (vanC2), E. flavescens CCUG 30567
(vanC3), E. faecium CCUG 47778 (vanD), E. faecalis
BM 4405 (vanE) and E. faecalis BM 4518 (vanG)
were included as controls. When this multiplex
PCR was performed on strain Hyg-39, amplifica-
tion fragments specific for vanD and E. faecium
were obtained.
To date, five distinct vanD alleles, vanD1–
vanD5, have been reported in enterococci [10–
15]. The sequence of the vanD PCR product from
Hyg-39 shared 100%, 93%, 90%, 89% and 88%
identity with the vanD5, vanD4, vanD2, vanD3 and
vanD1 alleles, respectively. VanD5 has been
reported previously in only one strain (N03-
0072) of E. faecium in Canada [11]. The Canadian
strain was isolated from a rectal ⁄perineal screen
of a female patient with a urinary tract infection
who had received multiple courses of vancomy-
cin. The MICs of vancomycin and teicoplanin for
N03-0072 were 64 mg ⁄L and 1 mg ⁄L, respect-
ively. The Swedish VanD5 isolate (Hyg-39) des-
cribed in the present report was isolated from the
urine of a liver transplant patient. The patient, a
male aged 58 years, had chronic hepatitis C
infection, liver cirrhosis and suspected liver can-
cer. Liver transplantation was undertaken in
February 2002. Post-operative complications
included arterial thrombosis, fever, sepsis,
bronchopneumonia and renal failure. Coagulase-
negative staphylococci, Acinetobacter and a-strep-
tococci were found in blood, drainage fluid and
bronchial secretions. Vancomycin, ciprofloxacin
and ceftazidime had been prescribed before the
isolation of Hyg-39 from urine. As has been
observed with other VanD-type E. faecium strains,
Hyg-39 was resistant to a relatively high level of
vancomycin (128 mg ⁄L) and to a low level of
teicoplanin (4 mg ⁄L). Hyg-39 was isolated during
April 2003, as was strain N03-0072 in Canada.
Similar to N03-0072, Hyg-39 was negative in a
PCR assay using the primer set designed from the
vanD1 sequence [14]. To our knowledge, Hyg-39
is the first VanD-type vancomycin-resistant en-
terococcal isolate reported in Sweden. The first
infection with a VanD-type glycopeptide-resistant
E. faecium strain in Europe was reported in France
during 2005, with an allele that showed the closest
relationship to VanD1 [10]. Hyg-39 is probably
the first VanD5 vancomycin-resistant enterococcal
isolate reported in Europe.
Since their first appearance in 1988, vancomy-
cin-resistant enterococci have emerged world-
wide and have become an increasing problem in
clinical settings [3]. Although several new anti-
microbial agents active against Gram-positive
pathogens have been introduced during recent
years, vancomycin remains a mainstay of treat-
ment for infection caused by susceptible staphy-
lococci and enterococci, thus continuing to
provide selective pressure for the further devel-
opment of resistant strains [4]. Resistance to
vancomycin developed first in enterococci, and
later in staphylococci [17]. As vancomycin resist-
ance continues to emerge in staphylococci and
enterococci, it is clear that infection control efforts
to interrupt the spread of these organisms in
healthcare settings should be reinforced.
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